Startseite UR
Publikationen von 0000-0002-4909-9588
(ORCID: 0000-0002-4909-9588)
 | Eine Stufe nach oben |
Anzahl der Einträge: 4.
2013
Seitz, Stephan, Buchholz, Stefan, Schally, Andrew V. 
, Jayakumar, Arumugam R., Weber, Florian, Papadia, Andrea , Rick, Ferenc G. , Szalontay, Luca, Treszl, Andrea, Köster, Frank, Ortmann, Olaf und Hohla, Florian
(2013)
Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124].
Anti-Cancer Drugs 24 (2), S. 150-157.
Volltext nicht vorhanden.
, Jayakumar, Arumugam R., Weber, Florian, Papadia, Andrea , Rick, Ferenc G. , Szalontay, Luca, Treszl, Andrea, Köster, Frank, Ortmann, Olaf und Hohla, Florian
(2013)
Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124].
Anti-Cancer Drugs 24 (2), S. 150-157.
Volltext nicht vorhanden.
2010
Hohla, Florian, Buchholz, Stefan, Schally, Andrew V. , Krishan, Awtar, Rick, Ferenc G. , Szalontay, Luca, Papadia, Andrea , Halmos, Gabor, Koster, Frank, Aigner, Elmar, Datz, Christian und Seitz, Stephan
(2010)
Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells.
Cancer Letters 294 (1), S. 35-42.
Volltext nicht vorhanden.
, Krishan, Awtar, Rick, Ferenc G. , Szalontay, Luca, Papadia, Andrea , Halmos, Gabor, Koster, Frank, Aigner, Elmar, Datz, Christian und Seitz, Stephan
(2010)
Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells.
Cancer Letters 294 (1), S. 35-42.
Volltext nicht vorhanden.
2009
Seitz, Stephan, Schally, Andrew V. , Treszl, Andrea, Papadia, Andrea , Rick, Ferenc , Szalontay, Luca, Szepeshazi, Karoly, Ortmann, Olaf, Halmos, Gabor, Hohla, Florian und Buchholz, Stefan
(2009)
Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition.
Anti-Cancer Drugs 20 (7), S. 553-558.
Volltext nicht vorhanden.
, Treszl, Andrea, Papadia, Andrea , Rick, Ferenc , Szalontay, Luca, Szepeshazi, Karoly, Ortmann, Olaf, Halmos, Gabor, Hohla, Florian und Buchholz, Stefan
(2009)
Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition.
Anti-Cancer Drugs 20 (7), S. 553-558.
Volltext nicht vorhanden.
Köster, , make_name_string expected hash reference, make_name_string expected hash reference , make_name_string expected hash reference , make_name_string expected hash reference , make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference , make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference und make_name_string expected hash reference
(2009)
Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist Cetrorelix with growth inhibition.
International Journal of Oncology 35 (4).
Volltext nicht vorhanden.
, make_name_string expected hash reference , make_name_string expected hash reference , make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference , make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference und make_name_string expected hash reference
(2009)
Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist Cetrorelix with growth inhibition.
International Journal of Oncology 35 (4).
Volltext nicht vorhanden.
Universitätsbibliothek
Publikationsserver
Kontakt:
Publizieren: oa@ur.de
0941 943 -4239 oder -69394
Dissertationen: dissertationen@ur.de
0941 943 -3904
Forschungsdaten: datahub@ur.de
0941 943 -5707